YEAR IN REVIEW
release of suPAR, which crossed the GFB and activated podocyte β 3 integrin in both native uPAR +/+ kidneys and transplanted uPAR -/-kidneys. The researchers also found that experi mentally sustained secretion of suPAR from sites outside the kidney induced FSGS. In addition, they found that serum suPAR level was significantly elevated in patients with primary FSGS (but not in those with minimal-change disease or membranous nephro pathy) compared with levels in healthy people; among those with FSGS, serum suPAR levels were highest in those who developed recurrent FSGS after transplanta tion. In patients in whom FSGS recurred, glomerular lesions showed activated podocyte β 3 integrin, and suPAR removed from serum by plasma pheresis correlated with remission of recurrent FSGS.
The results of this study provide a major breakthrough in the study of FSGS on several fronts. They identify a long-sought-after circulating factor that is causative of recurrent FSGS, is a potential biomarker for the development of or the risk of development of FSGS, and is a new potential therapeutic target for treating a disease in which current therapies show limited efficacy. Although not emphasized in the article, this study also provides suggestive evidence that FSGS may be an outcome of otherwise 'clinically silent' inflammation from environ mental pathogens. The marked upregulation of suPAR by lipopolysaccharide in mice suggests that chronic, heightened exposure to lipopolysaccharide or other pathogen-associated mol ecular patterns (PAMPs) derived from commensal or non-commensal microbes might cause elevated suPAR in humans, resulting in FSGS in susceptible individuals. 8 If found to be true, this hypothesis could lead to prophylactic strategies that manipulate the microbiome to lessen exposure and secondary damage to podocytes from these PAMPs.
Podocytes may also be injured by serving as sensors and not simply by being bystanders of environmental insults. The mammalian target of rapamycin (mTOR) signaling pathways are of great interest at present; sirolimus (also known as rapamycin), a drug that targets these pathways, is clinically useful in immune suppression, as an antiproliferative agent in cardiac stenting, and as a potential therapeutic agent for the treatment of renal cancer and polycystic disease. More recently it has been shown that mTOR pathways control aging in multiple model systems. In 2011, the mTOR pathway in podocytes emerged as a key molecular sensor of the nutrient environment. Godel, Huber and colleagues examined gene expression in microdissected glomeruli from human kidneys with early diabetic nephropathy. 9 They found marked upregulation of target genes of the mTOR pathway, suggesting that overactivation of this pathway in response to the dys regulated nutrient environment of diabetes contributes to the development of diabetic nephropathy. 9 To test this hypothesis, the authors bred mice haplo insufficient for mTORC1 in podocytes, thereby curtailing the activity of the mTOR pathway, and then induced experimental diabetic nephro pathy with streptozotocin. Intriguingly, the mice showed significant amelioration of diabetic nephropathy, clearly demonstrating that podocyte gene-environment interactions can drive the progression of diabetic nephropathy, and also identifying mTOR pathways as a potential thera peutic target to abrogate the progression of diabetic nephropathy.
This selection of studies published in 2011 highlight three seemingly disparate glomerular diseases, each with a different pathogenesis, but which together account for the majority of cases of nephrotic syndrome and end-stage renal disease in adults. Each of these studies has identified new and compelling mechanisms underlying glomerular injury. A common feature of these studies is that each also indicates the importance of under standing the complex role of the environ ment in mediating proteinuric glomerular diseases. Although we may continue to hope that gene replacement therapy can eliminate inheritable disease risks, we also need to identify concurrent modifiable environ mental factors to protect susceptible patients from developing disease. These studies are signaling the way forward in this quest.
POLYCYSTIC KIDNEY DISEASE IN 2011
Connecting the dots toward a polycystic kidney disease therapy
Vicente E. Torres and Peter C. Harris
Understanding the complex interactions between the various pathways disrupted in polycystic kidney and liver disease is essential to identify and optimize therapies for these disorders. Studies published in the past year have demonstrated a functional interaction between the main proteins implicated in these diseases and identified novel therapeutic approaches. 
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(ADPKD) detach from renal tubules and grow as blind sacs by a process that requires cell prolifera tion, net fluid secretion and remodeling of extracellular matrix. After the PKD1 and PKD2 genes and their encoded proteins, polycystin-1 and polycystin-2, were identified in 1994 and 1996, respectively, research in this area greatly accelerated. In the following years, genes mutated in autosomal recessive PKD (PKHD1 encoding fibro cystin) and in autosomal dominant polycystic liver disease (PRKCSH encoding glucosidase 2 subunit β, and SEC63 encoding translocation protein SEC63 homolog) were identified. Polycystin-1, polycystin-2 and fibrocystin are membrane glyco proteins, whereas glucosidase 2 subunit β and SEC63 are endoplasmic reticulum resident proteins needed for translocation and folding of integral membrane proteins and secreted proteins. Polycystin-1, polycystin-2 and fibrocystin have numerous interacting partners and their disruption affects multiple signaling pathways. Despite the multi plicity of genes and signaling pathways involved in PKD, interventions affecting many diverse targets have been effective in animal models of PKD, which indicates the presence of connections between the various pathways. Understanding these complex interactions will be essential to effectively treat PKD.
Fedeles et al. used mouse mutants to show that the main proteins implicated in ADPKD, autosomal recessive PKD and autosomal dominant polycystic liver disease functionally interact.
1 Loss of gluco sidase 2 subunit β or SEC63 reduces polycystin-1 and, to a lesser extent, polycystin-2 expression, blocks polycystin-1 trafficking to primary cilia, causes renal and hepatic cysts, worsens cystic disease in hetero zygous Pkd1 +/− and Pkd2 +/− mice and induces renal cystogenesis in Pkhd1 del 4/del 4 mice. Transgenic overexpression of poly cystin-1, but not polycystin-2, rescues the renal and hepatic pheno type of tissue-selective Prkcshknockout or Sec63-knockout mice and the renal phenotype of Pkhd1 del4/del4 mice. Polycystin-1 is the rate-limiting component in the polycystin-1/poly cystin-2 complex as its level of expression determines the severity of the cystic pheno type, but some functional polycystin-2 is essential for polycystin-1 to exert this effect. Immunocytochemical analysis revealed that the collecting duct is the segment most susceptible to the cystogenic effect of reduced polycystin-1 dosage. Proteasome inhibition increases poly cystin-1 levels and attenuates cystic disease in Prkcshknockout models, thus offering a conceptual therapeutic approach to auto somal dominant polycystic liver disease and possibly ADPKD.
The central role of cyclic AMP in PKD, and the ability to hormonally modulate cyclic AMP in a cell-specific manner, enables targeting of an important cystogenic pathway with relative safety. Among hormonal systems that affect renal cyclic AMP is the vasopressin-V2 receptor axis. This target is attractive because V2 receptors are mostly restricted to the thick ascending limb and collecting ducts, which are main sites of cystogenesis where vasopressin is the major agonist of cyclic AMP. These sites are continuously subjected to tonic vaso pressin action. Circulating vasopressin levels are increased in ADPKD and V2 receptors are overexpressed in polycystic kidneys. Pharmacological and genetic inhibition of vasopressin or V2 receptor expression has been shown to be effective in rodents. Reif et al. examined the effects of tolvaptan on human ADPKD cyst epithelial cells. 2 Low concentrations inhibited vasopressin-induced cyclic AMP production, cell prolifera tion, chloride secretion and cyst growth in collagen matrices. Other analyses showed that tolvaptan administration for 1 week reduced total kidney volume by 3.1% in patients with ADPKD, and that 3 years of tolvaptan therapy reduced kidney growth by 70% compared to historical controls (1.7% versus 5.8% increase per year, respectively). 3 Changes in kidney volume and in estimated glomerular filtration rate were significantly and negatively correlated. This finding supports the use of kidney volume as a biomarker to monitor ADPKD progression. Further evaluation of tolvaptan for the treatment of patients with ADPKD awaits the conclusion of a randomized, double-blind clinical trial (NCT00428948) in 2012.
Metformin and peroxisome proliferatoractivated receptor (PPAR)-γ agonists are widely used to treat type 2 diabetes melli tus. Takiar et al. found that metformin stimulates the energy-sensing molecule AMP-activated protein kinase (AMPK), inhibits the activities of AMPK-dependent cystic fibrosis transmembrane conductance regulator (CFTR) and mammalian target of rapamycin in Madin-Darby canine kidney renal epithelial cells, and attenuates cyclic AMP-dependent growth of Madin-Darby canine kidney cysts in collagen matrices and of cysts in metanephric organ explants, and cystogenesis in constitutive and inducible Pkd1-knockout mice. 4 Yoshihara et al. and Blazer-Yost et al. found that the PPAR-γ agonist pioglitazone inhibits renal and hepatic cystogenesis in PCK rats by possibly complementary mechanisms through the inactivation of mitogenactivated protein kinase 3 and mammalian target of rapa mycin, 5 and inhibition of CFTR synthesis and cyclic AMP-activated chloride secretion. 6 Because metformin and PPAR-γ agonists exert salutary effects by affecting the same pathways through different mechanisms (such as phosphoryla tion and inhibition of CFTR by metformin and inhibi tion of CFTR synthesis by pioglitazone), clinical trials of metformin and PPAR-γ agonist combinations in early ADPKD should be considered to exploit their possible synergism.
Evidence accumulated over the past two decades points to the importance of inflamma tion in PKD. Karihaloo et al. hypothesized that macrophage infiltration contributes to the proliferation of cyst-lining cells and PKD progression. 7 This premise was based on work showing that macrophages homing to the kidney after ischemiareperfusion undergo a transition from classically activated, pro inflammatory cells to alternatively activated cells that promote epithelial cell proliferation. The investigators found that Pkd1-null cells secrete large amounts of the macrophage chemoattractant C-C motif chemokine 2 (also known as monocyte chemotactic protein 1) and C-X-C motif chemokine 16. Kidneys from conditional Pkd1-knockout mice and the Pkd2 WS25/-mouse model of PKD2 exhibit a 10-fold increase in the number of How the loss of polycystin expression leads to increased cytokine production remains to be determined. Approaches that inhibit the expression or action of homing and proliferation signals provide novel strategies for treating PKD. Three studies have shown marked upregula tion of the signal transducer and transcription activator (STAT)3 in patients with ADPKD and in rodent PKD models. [8] [9] [10] In the STAT3 signaling pathway, activation of various cell surface growth factor receptors and cytokine receptors induces specific tyrosine phosphorylation of the receptors, which creates docking sites for latent cytoplasmic STAT3. STAT3 is then phosphorylated at tyrosine 705 by intrinsic tyrosine kinase activity of the activated growth factor receptors or by cytokine receptor-associated Janus kinase. The trigger for phosphorylation and activation of STAT3 in PKD is uncertain. Talbot et al. showed that phosphorylated STAT3 is highly expressed in cyst-lining cells and normal-appearing tubules and inter stitial cells in proximity to cysts. 8 This finding suggests that diffusible factors such as cytokines and growth factors are involved in the activation of STAT3. Phosphorylated STAT3 homodimers translocate to the nucleus and bind to promoter elements of genes that regulate cell differentiation, proliferation, apoptosis and angiogenesis. Because STAT3 is critical during development (deletion of STAT3 leads to embryonic lethality), but is dispensable postnatally in conditional knockouts, targeting STAT3 might be well tolerated in patients with PKD. Takakura et al. screened a small-molecule library using a cell-based functional assay and found that pyrimethamine, a drug used to treat malaria and toxoplasmosis, inhibits STAT3 signaling. 9 Pyrimethamine and S3I-201, an inhibitor of STAT3 homodimer complex formation, suppressed epithelial cell proliferation and cystogenesis in an inducible Pkd1-knockout mouse model without toxic effects. In another study, Leonhard et al. found that curcumin, a compound with anti-inflammatory and antiproliferative properties, reduced STAT3 activation, attenuated cell proliferation and cysto genesis and delayed renal failure from 105 to 119 days in an inducible Pkd1-knockout model. 10 As curcumin has poor bioavailability, however, novel analogues with improved pharmacological profiles might be more effective than curcumin itself.
In summary, insights into the complex network of signaling pathways disrupted in PKD have increasingly led to the identification of potential therapies, some of which are currently used for other indications. Those compounds best supported by preclinical studies and with the desired pharmacological profile should be prioritized for clinical trials. 
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